Abstract：
UNASSIGNED: We systematically reviewed extant studies evaluating the efficacy and tolerability of xanomeline and xanomeline-trospium (KarXT) for treatment of adults with schizophrenia.
UNASSIGNED: In accordance with PRISMA guidelines, articles were systematically searched for in databases and clinical trial registries.
UNASSIGNED: A total of 4 preclinical trials and 3 randomized controlled trials (RCTs) were included in this review. A 4-week RCT observed a difference of 24.0 points (SD 21.0) in the Positive and Negative Syndrome Scale (PANSS) total score between xanomeline and placebo groups (p = 0.039). A 5-week RCT observed PANSS total score changes from baseline to week 5, including -17.4 and -5.9 points in KarXT and placebo groups, respectively (LSMD -11.6 points; 95% CI -16.1 to -7.1; p < 0.001; d = 0.75). Another 5-week RCT observed PANSS total score changes from baseline to week 5, including -21.2 (SE 1.7) and -11.6 (SE 1.6) points in KarXT and placebo groups, respectively (LSMD -9.6; 95% CI -13.9 to -5.2; p < 0.0001; d = 0.61). Side effects include constipation, nausea, vomiting, dyspepsia, and dry mouth.
UNASSIGNED: KarXT offers an innovative non-D2 blocking approach, representing a promising treatment avenue for schizophrenia.
UNASSIGNED: In accordance with PRISMA guidelines, articles were systematically searched for in databases and clinical trial registries.
UNASSIGNED: A total of 4 preclinical trials and 3 randomized controlled trials (RCTs) were included in this review. A 4-week RCT observed a difference of 24.0 points (SD 21.0) in the Positive and Negative Syndrome Scale (PANSS) total score between xanomeline and placebo groups (p = 0.039). A 5-week RCT observed PANSS total score changes from baseline to week 5, including -17.4 and -5.9 points in KarXT and placebo groups, respectively (LSMD -11.6 points; 95% CI -16.1 to -7.1; p < 0.001; d = 0.75). Another 5-week RCT observed PANSS total score changes from baseline to week 5, including -21.2 (SE 1.7) and -11.6 (SE 1.6) points in KarXT and placebo groups, respectively (LSMD -9.6; 95% CI -13.9 to -5.2; p < 0.0001; d = 0.61). Side effects include constipation, nausea, vomiting, dyspepsia, and dry mouth.
UNASSIGNED: KarXT offers an innovative non-D2 blocking approach, representing a promising treatment avenue for schizophrenia.
摘要：
■我们系统回顾了现有研究，这些研究评估了xanomeline和xanomeline-trosspium（KarXT）治疗成人精神分裂症的疗效和耐受性。
■根据PRISMA指南，在数据库和临床试验登记处系统检索了文章.
■本综述共纳入4项临床前试验和3项随机对照试验（RCT）。4周的RCT观察到xanomeline组和安慰剂组之间的阳性和阴性综合征量表（PANSS）总分差异为24.0分（SD21.0）（p=0.039）。5周的RCT观察到PANSS总分从基线到第5周的变化，包括KarXT和安慰剂组的-17.4和-5.9分，分别（LSMD-11.6分；95%CI-16.1至-7.1；p<0.001；d=0.75）。另一个5周的RCT观察到PANSS总分从基线到第5周的变化，包括KarXT和安慰剂组的-21.2（SE1.7）和-11.6（SE1.6）分，分别(LSMD-9.6；95%CI-13.9至-5.2；p<0.0001；d=0.61)。副作用包括便秘,恶心,呕吐,消化不良,口干。
■KarXT提供了一种创新的非D2阻塞方法，代表精神分裂症有希望的治疗途径。
■根据PRISMA指南，在数据库和临床试验登记处系统检索了文章.
■本综述共纳入4项临床前试验和3项随机对照试验（RCT）。4周的RCT观察到xanomeline组和安慰剂组之间的阳性和阴性综合征量表（PANSS）总分差异为24.0分（SD21.0）（p=0.039）。5周的RCT观察到PANSS总分从基线到第5周的变化，包括KarXT和安慰剂组的-17.4和-5.9分，分别（LSMD-11.6分；95%CI-16.1至-7.1；p<0.001；d=0.75）。另一个5周的RCT观察到PANSS总分从基线到第5周的变化，包括KarXT和安慰剂组的-21.2（SE1.7）和-11.6（SE1.6）分，分别(LSMD-9.6；95%CI-13.9至-5.2；p<0.0001；d=0.61)。副作用包括便秘,恶心,呕吐,消化不良,口干。
■KarXT提供了一种创新的非D2阻塞方法，代表精神分裂症有希望的治疗途径。
